Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 CAR-T cells (Chinese PLA General Hospital)
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19 CAR-T cells (Chinese PLA General Hospital) is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by the Chinese PLA General Hospital for the treatment of various refractory B-cell mediated autoimmune diseases. The therapy involves the genetic modification of a patient's own T cells to express a CAR that specifically targets the CD19 antigen, a protein found on the surface of B lymphocytes. By targeting and depleting these B cells, the therapy aims to eliminate the source of pathogenic autoantibodies and reset the immune system. It is currently being evaluated in a Phase 1 clinical trial (NCT05849922) for a broad range of indications, including systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathies, ANCA-associated vasculitis, Sjögren's syndrome, antiphospholipid syndrome, immune thrombocytopenia, and pemphigus.
- Other names
- CAR-T cell therapy (Chinese PLA General Hospital)anti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cellsCAR-T cell
02
Targets
Beyond the preview
Go deeper on CD19 CAR-T cells (Chinese PLA General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 CAR-T cells (Chinese PLA General Hospital).